ATE414789T1 - Marker für lungentumore - Google Patents

Marker für lungentumore

Info

Publication number
ATE414789T1
ATE414789T1 AT02010275T AT02010275T ATE414789T1 AT E414789 T1 ATE414789 T1 AT E414789T1 AT 02010275 T AT02010275 T AT 02010275T AT 02010275 T AT02010275 T AT 02010275T AT E414789 T1 ATE414789 T1 AT E414789T1
Authority
AT
Austria
Prior art keywords
tumors
nucleic acids
marker
lung cancer
relates
Prior art date
Application number
AT02010275T
Other languages
English (en)
Inventor
Johannes Coy
Rainer Hipfel
Birgit Wasser
Original Assignee
Mtm Lab Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mtm Lab Ag filed Critical Mtm Lab Ag
Application granted granted Critical
Publication of ATE414789T1 publication Critical patent/ATE414789T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
AT02010275T 2002-05-21 2002-05-21 Marker für lungentumore ATE414789T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP20020010275 EP1365032B1 (de) 2002-05-21 2002-05-21 Marker für Lungentumore

Publications (1)

Publication Number Publication Date
ATE414789T1 true ATE414789T1 (de) 2008-12-15

Family

ID=29286116

Family Applications (2)

Application Number Title Priority Date Filing Date
AT02010275T ATE414789T1 (de) 2002-05-21 2002-05-21 Marker für lungentumore
AT03735709T ATE389033T1 (de) 2002-05-21 2003-05-16 Marker fur lungentumoren

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT03735709T ATE389033T1 (de) 2002-05-21 2003-05-16 Marker fur lungentumoren

Country Status (9)

Country Link
US (2) US7355025B2 (de)
EP (2) EP1365032B1 (de)
JP (2) JP4520848B2 (de)
AT (2) ATE414789T1 (de)
AU (1) AU2003238077A1 (de)
CA (1) CA2486583C (de)
DE (2) DE60229920D1 (de)
ES (2) ES2316501T3 (de)
WO (1) WO2003097871A2 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11927591B2 (en) 2016-08-02 2024-03-12 Georgetown University Methods of identifying novel proteins and antigens in cancer cells
WO2021030268A2 (en) 2019-08-09 2021-02-18 Nutcracker Therapeutics, Inc. Microfluidic apparatus and methods of use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4281061A (en) * 1979-07-27 1981-07-28 Syva Company Double antibody for enhanced sensitivity in immunoassay
US6316208B1 (en) * 1994-01-07 2001-11-13 Memorial Sloan-Kettering Cancer Center Methods for determining isolated p27 protein levels and uses thereof
US6033847A (en) * 1995-02-06 2000-03-07 St. Jude Children's Research Hospital InK4c-p18 and InK4d-p19, inhibitors of cyclin-dependent kinases CDK4 and CDK6, and uses thereof
US5858683A (en) * 1996-08-30 1999-01-12 Matritech, Inc. Methods and compositions for the detection of cervical cancer
JP2003516716A (ja) * 1999-06-16 2003-05-20 ザ ジョン ホプキンス ユニバーシティー 酵母トランスクリプトームの特徴付け
US6806254B2 (en) * 2000-02-03 2004-10-19 Nuvelo, Inc. Methods and materials relating to alpha-2-macroglobulin-like polypeptides and polynucleotides
JP2003525599A (ja) * 2000-02-17 2003-09-02 ディアデクサス インコーポレーテッド 肺癌特異的遺伝子による肺癌の診断、モニタリング、病期分類、イメージングおよび治療の方法
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
US20040241651A1 (en) * 2000-04-07 2004-12-02 Alexander Olek Detection of single nucleotide polymorphisms (snp's) and cytosine-methylations
AU2001276919A1 (en) * 2000-07-13 2002-01-30 Genaissance Pharmaceuticals, Inc. Haplotypes of the mmp13 gene

Also Published As

Publication number Publication date
JP4520848B2 (ja) 2010-08-11
JP2010017194A (ja) 2010-01-28
US7355025B2 (en) 2008-04-08
ES2303595T3 (es) 2008-08-16
DE60319693D1 (de) 2008-04-24
WO2003097871A8 (en) 2004-03-04
EP1506317A2 (de) 2005-02-16
WO2003097871A3 (en) 2004-02-05
AU2003238077A1 (en) 2003-12-02
JP2005525826A (ja) 2005-09-02
ES2316501T3 (es) 2009-04-16
US20090098544A1 (en) 2009-04-16
AU2003238077A8 (en) 2003-12-02
US7883896B2 (en) 2011-02-08
EP1365032B1 (de) 2008-11-19
ATE389033T1 (de) 2008-03-15
DE60319693T2 (de) 2009-03-05
CA2486583C (en) 2013-09-24
CA2486583A1 (en) 2003-11-27
US20050176930A1 (en) 2005-08-11
EP1506317B1 (de) 2008-03-12
WO2003097871A2 (en) 2003-11-27
EP1365032A1 (de) 2003-11-26
DE60229920D1 (de) 2009-01-02

Similar Documents

Publication Publication Date Title
WO2004092338A3 (en) Compositions, splice variants and methods relating to cancer specific genes and proteins
HRP20211419T1 (hr) Predviđanje epitopa t-stanica korisnih za cijepljenje
WO2005108415A3 (en) Membrane associated molecules
WO2010093872A3 (en) Molecular-based method of cancer diagnosis and prognosis
WO2008031839A3 (en) Gene expression signature for the prognosis, diagnosis, and therapy of prostate cancer and uses thereof
WO2011027308A8 (en) Novel tumor markers
WO2004106495A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
WO2002062945A3 (en) Compositions and methods relating to lung specific genes and proteins
WO2005032495A3 (en) Gene expression profiles and methods of use
BR9915732A (pt) Geração de anticorpos usando-se vacinação de polinucleotìdeo em espécie de ave
DK1109021T3 (da) Snail, en ny tumoral progressionsmarkör og et targetprotein for nye antitumorale forbindelser
EA201290107A1 (ru) Способ определения пациента как восприимчивого или не восприимчивого к иммунотерапии
ATE534902T1 (de) Replikationsproteinn ciz1
WO2007000320A3 (de) Verfahren zur diagnose von rheumatischen erkrankungen
DE60229920D1 (de) Marker für Lungentumore
DE69834949T8 (de) Bestimmung der prädisposition für obstruktive lungenerkrankung basierend auf genpolymorphismen der humanen luftweg-trypsin-protease
WO2011027311A3 (en) Novel tumor markers
WO2011073905A8 (en) Novel tumor markers
WO2009019366A3 (fr) Procede de dosage de l'aminoacylase 1 pour le diagnostic in vitro du cancer colorectal
WO2005017183A3 (en) Methylated gene biomarkers for detecting cancer
DE602005017788D1 (de) Diagnose- und prognoseverfahren der nichtalkoholischen steatohepatitis (nash)
WO2008037720A3 (en) Means and methods for diagnosing and/or treating a subject at risk of developing heart failure
WO2004013631A3 (en) Compositions and methods for diagnosis and therapy of cancer
WO2002064788A3 (en) Compositions and methods relating to lung specific genes and proteins
WO2004050858A3 (en) Compositions, splice variants and methods relating to colon specific genes and proteins

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties